Ibio Inc

iBio Inc (IBIO) is a small-cap biotechnology company focused on developing biologics and therapeutic candidates, often using platform technologies to accelerate discovery and manufacturing. With a market capitalisation roughly $22.5m, IBIO is a micro‑cap equity with typical characteristics of early‑stage biotech: potential for upside tied to scientific or regulatory progress, but also meaningful operational, clinical and funding risk. Investors should note the company’s outcome sensitivity to research results, partnership deals and cash runway; many companies at this size raise capital periodically, which can dilute existing shareholders. Public information on revenues and profitability may be limited, so assessment typically centres on the pipeline, intellectual property, collaborators and management track record. For UK and EU investors, consider currency and regulatory differences. This summary is educational only, not personalised financial advice. Biotechnology stocks can be volatile and you could lose some or all of your investment; check suitability with a qualified adviser before investing.